Debbie Orr
Adult Health · Camden, NJNPI 1023410552
Payments from drug & device makers
Across 164 payments — averaging $12.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Pfizer$154
- AstraZeneca$122
- Novo Nordisk$61
- Cardiovascular Systems Inc.$38
- Bayer$37
- plus $196 from 8 others
What the payments were for
- Food & beverage$2,130100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 125 | $1,521 |
| Pfizer | 11 | $154 |
| AstraZeneca | 8 | $122 |
| Novo Nordisk | 4 | $61 |
| Cardiovascular Systems Inc. | 2 | $38 |
| Bayer | 2 | $37 |
| Boston Scientific | 2 | $36 |
| W. L. Gore & Associates, Inc. | 2 | $35 |
| Medtronic | 2 | $30 |
| Chiesi USA, Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $19 |
| Johnson & Johnson | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
How this compares
$2,130 in reported general payments places this provider in the 80th percentile of 1,135 adult health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 24 | $16,207 |
| BrilintaTicagrelor | 33 | $14,419 |
| EliquisApixaban | 19 | $12,935 |
| FarxigaDapagliflozin Propanediol | 11 | $6,127 |
| ClopidogrelClopidogrel Bisulfate | 91 | $1,519 |
| Atorvastatin Calcium | 68 | $851 |
| Metoprolol Succinate | 41 | $470 |
| Rosuvastatin Calcium | 27 | $295 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $192 |
| Carvedilol | 41 | $181 |
| Bumetanide | 11 | $180 |
| Furosemide | 23 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $122 | $20,54744 claims |
| NovartisEntresto | $19 | $16,20724 claims |
| PfizerEliquis | $154 | $12,93519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Camden
- Kara SaggiomoCamden$127K
- Phyllis DudaCamden$46K
- June HalperHackensack$458K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.